{"filings":[{"id":798916,"accession_number":"0001213900-26-064037","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2026-06-02T17:16:53+00:00","items":["1.01","9.01"],"status":"ready","headline":"OSR Holdings enters $30M asset purchase agreement with subsidiary Vaximm for VXM01 IP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$30M purchase price for VXM01 IP; payment deferred until first milestone payment under existing license (Phase 2 completion).","Milestone trigger: completion of Phase 2 study of VXM01 in glioblastoma or pancreatic cancer.","Buyer may make voluntary partial payments before milestone; full balance due on milestone date.","Related-party transaction with subsidiary Vaximm; agreement aimed at Swiss transfer pricing simplification.","Closing occurs upon full payment; no effect on asset transfer if payment default, subject to good faith resolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96088,"accession_number":"0001213900-26-052922","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K/A","filed_at":"2026-05-06T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"OSR Holdings files fairness opinion for $815M VXM01 license deal with BCME","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Fairness opinion values VXM01 standalone risk-adjusted NPV at ~$93.4M median; deal offers up to $815M milestone payments, no upfront.","BCME, OSRH's largest shareholder, is licensee; transaction is related-party; opinion deems terms fair to unaffiliated shareholders.","Equity participation right: OSRH can issue up to $15M common at $10/share (~1,567% premium to $0.60 market) at its discretion.","Royalty pass-through: BCME recovers a preferred return (up to 15% compounded) from downstream royalties before passing 100% to OSRH.","Blockchain-based TAC token mechanism excluded from fairness opinion; may require separate opinion or deletion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96092,"accession_number":"0001213900-26-049967","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"OSR Holdings signs $815M VXM01 license with BCM Europe; largest shareholder pledges entire stake as collateral","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $815M in milestone payments from BCM Europe for VXM01 oral immunotherapy platform (Phase 3-ready VEGFR-2 target).","BCM Europe pledges its entire 9,974,728 shares (~29.7% of OSRH) as collateral for milestone obligations; pledge effective Feb 2028.","OSRH to acquire full VXM01 IP from Vaximm AG for $30M via separate asset purchase agreement.","OSRH receives $15M equity put option at $10/share, exercisable after six months post-effective date.","All downstream royalties after BCME recovers investment and preferred return flow to OSRH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96091,"accession_number":"0001213900-26-046711","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OSR Holdings appoints Yeiseok Kim as COO effective April 16, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kim previously served as Senior Analyst at OSR Holdings Co., Ltd. subsidiary from 2020-2025.","Base salary of KRW 240,000,000 per year plus discretionary equity compensation under company plan.","Kim holds a Korean medical license and has experience in cross-border healthcare investments and pharmaceutical licensing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96090,"accession_number":"0001213900-26-041768","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"OSR Holdings eliminates $2.02M warrant overhang via $1.06M note at $1.00 conversion (100% premium)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Retired approx. $2.02M in outstanding warrants via issuance of $1.06M senior secured convertible note to White Lion Capital.","Note has fixed conversion price of $1.00/share (~100% premium to April 8 closing price of ~$0.49).","Company received $500k cash; remaining ~$2.02M warrant liability eliminated; note matures in 9 months, 5% interest.","Note includes six-month conversion restriction, preventing immediate dilution and supporting trading stability.","Transaction aims to reduce structural overhang and support Nasdaq minimum bid compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96087,"accession_number":"0001213900-26-039691","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K/A","filed_at":"2026-04-03T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"OSR Holdings (OSRH) Enters Binding Term Sheet for VXM01 License with BCM Europe; $815M Milestones, $30M Facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["The binding term sheet grants BCM Europe exclusive worldwide rights to VXM01, with OSR Holdings providing up to $30M development financing to Vaximm AG.","BCM Europe Fund will pay up to $815M in milestone payments directly to OSR Holdings upon clinical and regulatory achievements.","OSR Holdings retains an equity option to issue up to $15M of common stock at $10/share (premium to market) to BCME Fund.","Royalties from an ultimate licensee will pass through to OSR Holdings after recovery of a negative milestone delta and minimum preferred return.","The transaction is a related-party deal requiring an independent fairness opinion; the term sheet supersedes a prior January 2026 term sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96089,"accession_number":"0001213900-26-039278","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"OSR Holdings signs binding term sheet for VXM01 license; up to $815M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Vaximm grants BCME exclusive worldwide license to develop and commercialize VXM01; OSRH is primary recipient of milestone payments.","BCME responsible for up to $815M in milestone payments payable to OSRH; OSRH to provide Vaximm $30M development financing facility.","Related-party transaction as BCME is OSRH's largest shareholder; independent fairness opinion required before definitive agreement.","OSRH retains option to issue up to $15M of common stock at $1.00 per share to BCME Fund, exercisable at OSRH's discretion after 6 months.","Royalties from ultimate licensee pass through to OSRH after BCME recovers a negative milestone delta including up to 15% preferred return."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109689,"accession_number":"0001213900-26-027984","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"OSR Holdings discloses Pexa-Vec license talks and potential SillaJen controlling stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vaximm in active negotiations with SillaJen to license Pexa-Vec, a Phase 2 oncolytic immunotherapy for renal cell carcinoma.","OSR Holdings held preliminary verbal talks to acquire ~16% controlling stake in SillaJen (KOSDAQ:215600).","No binding term sheet, letter of intent, or definitive agreement exists for either matter.","Disclosed to comply with Regulation FD after inadvertent reference during March 13 analyst call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109688,"accession_number":"0001213900-26-025428","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"OSR Holdings gets Nasdaq extension to Aug 31, 2026 for $1 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted additional 180-day period until Aug 31, 2026 to regain minimum $1.00 closing bid price.","Initial compliance period ended Mar 4, 2026; company had fallen below $1.00 for 30 consecutive business days.","Company must show closing bid price ≥ $1.00 for 10 consecutive business days to regain compliance.","OSR Holdings meets all other Nasdaq Capital Market initial listing requirements except bid price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109687,"accession_number":"0001213900-26-007987","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"OSR Holdings completes Woori IO acquisition; legacy shareholders lock $10/share exchange, reviews subsidiary combination","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Woori IO closed Jan 26, 2026; WORIO becomes indirect wholly-owned subsidiary via share exchange (84,338 OSRK shares for 88,891 WORIO shares).","Legacy Woori IO shareholders reaffirmed three-year equity alignment; they may exchange OSRK equity only at $10.00/share, preventing near-term dilution.","OSRH initiates strategic review of combining Woori IO and RMC into a new medical device company; potential standalone IPO in Korea under evaluation.","No OSRH common stock issued in transaction; acquisition funded through subsidiary equity interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109686,"accession_number":"0001213900-26-004199","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"OSR Holdings subsidiary Vaximm gets binding term sheet for VXM01 license: $30M upfront, $815M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Vaximm, OSR Holdings' subsidiary, enters binding term sheet with BCM Europe for global exclusive license of VXM01.","Upfront payment of $30M (50% cash, 50% digital assets) and up to $815M in clinical, regulatory, and commercial milestones.","Definitive agreement targeted by end of May 2026, subject to fairness opinion, board review, and final documentation.","BCM Europe, the largest OSRH shareholder, will establish a fund (BCM Decentralized Science Investors I) as licensee.","VXM01 is an oral T-cell vaccination platform targeting VEGFR-2; has shown clinical activity and safety in multiple cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126204,"accession_number":"0001213900-25-114496","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OSR Holdings subsidiary Vaximm enters term sheet with BCM Europe for VXM01 license; $20M upfront, up to $815M milestones","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Non-binding term sheet with BCM Europe AG for exclusive global license of VXM01 oral cancer immunotherapy.","Potential $20M upfront payment plus up to $815M in clinical, regulatory, and commercial milestones.","Six-month exclusivity period for negotiations; due diligence and board approvals required.","BCM Europe is OSRH's largest shareholder; deal includes optional blockchain-based royalty mechanism (TAC tokens).","Vaximm retains IP ownership; definitive agreement would grant BCME exclusive global rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126203,"accession_number":"0001213900-25-099393","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"OSRH acquires WORIO for $10.6M in stock; non-invasive glucose monitoring tech","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["OSRH subsidiary OSRK to acquire WORIO via share exchange for KRW 15B (~USD 10.6M). WORIO becomes indirect wholly owned subsidiary.","WORIO develops needle-free continuous glucose monitor using NIRS technology; has an active partnership with Samsung for clinical trials with non-dilutive funding.","Each WORIO share exchanged for 0.948832 OSRK shares; OSRK issues 84,338 new shares for 88,891 WORIO shares.","If OSRH stock reaches $10 within 3 years, OSRK shares may convert into OSRH common at 12.96:1 ratio, up to ~1.09M new shares.","Closing expected Jan 12, 2026, subject to WORIO shareholder vote (Dec 19, 2025) and regulatory clearances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142947,"accession_number":"0001213900-25-090340","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OSR Holdings annual meeting elects 7 directors; two nominees not elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected 7 of 9 director nominees; Jin Whan Park and Phil Geon Lee were not elected.","Executive compensation proposal approved: 13,297,569 for, 27,228 against, 894 abstain.","Equity plan proposal approved: 13,302,163 for, 22,669 against, 859 abstain.","Nasdaq 20% issuance proposal approved: 13,288,524 for, 36,490 against, 677 abstain.","Quorum of 13,325,691 shares (61.73% outstanding) present at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142946,"accession_number":"0001213900-25-086209","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"OSR Holdings receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sept 5, 2025; common stock bid price below $1.00 for 30 consecutive business days.","Has 180 days, until March 4, 2026, to regain compliance by closing at $1.00 for 10 consecutive business days.","If not compliant by March 4, may get additional 180 days if meets other listing standards and notifies intent to cure.","Company considering options including potential reverse stock split to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142945,"accession_number":"0001213900-25-085670","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"OSR Holdings sued by Chardan Capital Markets for $2.07M and 34,500 shares","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Chardan filed action in SDNY on Sept 2, 2025 seeking ~$2,070,000 and 34,500 deferred equity shares.","Lawsuit relates to matters previously disclosed in OSRH's August 14, 2025 Form 10-Q.","OSR Holdings and CEO Kuk Hyoun Hwang plan to defend against the claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142944,"accession_number":"0001213900-25-079053","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"OSR Holdings Amends Agreements with White Lion to Require Stockholder Meeting by Sept 19, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Note Purchase Agreement requires stockholder meeting before Sept 19, 2025 to approve issuances exceeding 19.99% Nasdaq Exchange Cap.","Failure to convene meeting triggers $400,000 liquidated damages payable immediately in cash to White Lion.","Amendment to Common Stock Purchase Warrant imposes similar stockholder approval deadline; failure allows White Lion to adjust exercise price to $0.01.","Both amendments effective June 30, 2025, and signed by CEO Kuk Hyoun Hwang and White Lion managing director Yash Thukral."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142943,"accession_number":"0001213900-25-072321","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OSR Holdings files investor presentation for August 6 event; no financial details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Held investor event on August 6, 2025; presentation attached as Exhibit 99.1.","Presentation made available on company's investor relations website.","Filing contains no earnings results, guidance changes, or material operational updates.","No specific numbers, strategic initiatives, or forward-looking statements included in the 8-K.","Company's tickers: OSRH (common) and OSRHW (warrants) on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142942,"accession_number":"0001213900-25-067798","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OSR Holdings enters term sheet to acquire Woori IO for noninvasive glucose monitoring tech","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Non-binding term sheet: OSRK to acquire WORIO via share exchange; WORIO shareholders receive OSRK shares convertible into OSRH common stock.","Conversion conditional on OSRH stock reaching $10.00 within 3 years; fixed ratio 1 OSRK = 12.96 OSRH shares.","6-month exclusivity period for due diligence; parties aim to complete transaction within that period.","WORIO's platform uses near-infrared spectroscopy (NIRS) for noninvasive glucose monitoring; completed proof-of-concept with Korea University Hospital.","Glucose monitoring devices market projected to exceed $40B by 2030; WORIO selected by Samsung C-Lab Outside in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142941,"accession_number":"0001213900-25-060679","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Sang Hyun Kim resigns from OSR Holdings board effective June 26, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sang Hyun Kim resigned as independent director, effective immediately on June 26, 2025.","Resignation was not due to any dispute or disagreement with the company.","No replacement director has been named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161020,"accession_number":"0001213900-25-042018","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"OSR Holdings enters financing agreements with White Lion Capital for $1.11M convertible notes and $78.9M ELOC","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Secured $1,110,000 in convertible notes at 5% interest; first $400,000 due after S-1 filing, second $600,000 after effective date.","Warrants issued for up to $4,000,000 in shares at $1.584 per share, exercisable for 5 years; conversion at 95% of lowest 15-day VWAP.","ELOC amended to allow OSR to sell up to $78.9M in common stock to White Lion, subject to daily volume and pricing limitations.","Conversion capped at 4.99% of shares outstanding; 10% of ELOC proceeds allocated to note repayment.","No material non-public information disclosed; reliance on exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161019,"accession_number":"0001213900-25-034120","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K/A","filed_at":"2025-04-22T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"OSR Holdings files audited FY2024 financials for Legacy OSR; net loss widens to ₩14.1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of ₩14.09B (₩7,466 per share) for 2024 vs ₩13.61B loss in 2023 on revenue of ₩4.82B (+8% YoY).","Operating loss increased to ₩15.95B from ₩14.78B; SG&A expenses grew to ₩17.05B.","Total assets ₩257.6B, equity ₩210.5B; cash and equivalents dropped to ₩502M from ₩697M.","Key subsidiaries: VAXIMM (Switzerland, biotech), RMC (medical devices, Korea), Darnatein (biotech, Korea)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179219,"accession_number":"0001013762-25-001833","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"OSR Holdings appoints Dr. Constance Höfer as Chief Scientific Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Höfer appointed CSO effective March 24, 2025; oversees scientific strategy and innovation pipeline.","Over 20 years experience in oncology/immunology; previously led global programs at Merck Healthcare.","Employment agreement: $300,000 base salary plus equity compensation and customary benefits.","No family relationships with directors/officers and no reportable related-party transactions.","Appointment aims to strengthen R&D capabilities and accelerate drug development across multiple modalities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179218,"accession_number":"0001213900-25-018204","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"OSR Holdings enters $80M equity purchase agreement with White Lion Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may require White Lion to purchase up to $80M of common stock via Rapid or VWAP purchase notices.","Each purchase notice capped at $2M; pricing based on lowest three traded prices (Rapid) or 97% of lowest daily VWAP (VWAP).","Commitment shares worth $800K to be issued to White Lion as consideration for the commitment.","Resale registration statement must be filed within 30 days after closing of the Business Combination.","Agreement terminates December 31, 2026 or upon bankruptcy; provides flexible capital access but dilutive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179217,"accession_number":"0001213900-25-016100","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01","2.01","5.06","5.02","3.03","5.03","5.01","9.01"],"status":"ready","headline":"OSR Holdings completes reverse merger with OSR Korea; begins trading as OSRH","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issued 16,282,047 shares to acquire ~67% of OSR Korea; total shares outstanding 19,276,978.","Kuk Hyoun Hwang beneficially owns 67.8% of OSRH common stock post-closing.","Lock-up agreements restrict 70-100% of certain holder shares for up to 36 months.","Company ceased being a shell company; common stock and warrants trade on Nasdaq under OSRH/OSRHW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179216,"accession_number":"0001213900-25-014490","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OSR Holdings completes business combination with OSR Co., Ltd.; begins trading Feb 18 under OSRH","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business combination with OSR Holdings Co., Ltd. closed on February 14, 2025.","Common stock and warrants to trade on Nasdaq starting February 18, 2025, under OSRH and OSRHW.","Company formerly known as Bellevue Life Sciences Acquisition Corp. (BLAC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179215,"accession_number":"0001213900-25-013498","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.03","5.07","8.01","9.01"],"status":"ready","headline":"BLAC stockholders approve business combination with OSR Holdings; name change to OSR Holdings, Inc.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All proposals approved at Feb 13 special meeting; 93.95% quorum; 57,821 shares redeemed.","Transaction expected to close Feb 14 after foreign investment approval from Industrial Bank of Korea.","Post-close, OSR Holdings will own ~67% of OSR; additional 22% subject to put/call from 2026.","New tickers OSRH (common) and OSRHW (warrants) begin trading on Nasdaq Feb 18.","Nine directors elected; portfolio includes Phase 2 immunotherapy, age-related therapies, medical device distribution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179214,"accession_number":"0001213900-25-005957","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bellevue Life Sciences extends sponsor promissory notes maturity to Sept 30, 2025 regardless of business combination","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second amendment removes earlier condition that notes matured on earlier of Sept 30, 2025 or business combination close.","Four promissory notes from sponsor Bellevue Global Life Sciences Investors, LLC aggregate $1.69M principal.","All other terms remain unchanged; notes are unsecured and governed by existing covenants.","Amendment executed January 23, 2025; previous amendment dated January 9, 2025 extended to Sept 30, 2025 or deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179213,"accession_number":"0001193125-25-004439","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bellevue Life Sciences extends sponsor promissory notes maturity to Sep 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of four promissory notes (totaling $1.69M) to earlier of Sept 30, 2025 or deal close.","Notes from April 8, April 17, May 14, and July 11, 2024 in amounts $1.2M, $50K, $140K, $300K.","No other terms amended; interest and other provisions unchanged.","Sponsor Bellevue Global Life Sciences Investors, LLC is the noteholder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195898,"accession_number":"0001193125-24-283685","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BLAC amends PIPE to remove redemption features; modifies OSR deal put/call terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE amendment removes redemption features from 222,222 Series A Preferred shares (Toonon, $20M at $90/share).","Business combination amendment adds termination date (120 days after Trigger Date) for Non-Participating Stockholder put/call rights.","Trigger Date is Jan 1, 2026 or upon Change in Control notification; BLAC must provide 20 business days' notice.","CEO Kuk Hyoun Hwang is also OSR Chairman; M&A Committee of independent directors approved both amendments.","S-4 registration statement remains pending; definitive proxy statement to be mailed to BLAC stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195897,"accession_number":"0001193125-24-256062","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.03","5.07","8.01","9.01"],"status":"ready","headline":"Stockholders approve extension of Bellevue Life Sciences SPAC deadline to Feb 2025; 44% of shares redeemed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter amended to extend business combination deadline from Nov 14, 2024 to Feb 14, 2025.","Charter amended to remove net tangible asset requirement to avoid penny stock rules.","1,766,469 shares (approx. 44% of outstanding) tendered for redemption.","Five existing directors re-elected at annual meeting.","Quorum was 71.24% of outstanding shares; proposals approved overwhelmingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195896,"accession_number":"0001193125-24-244725","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bellevue Life Sciences advances $300K loan to OSR Holdings at 3.96% annual interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan of $300,000 to OSR Holdings, target of proposed business combination, evidenced by promissory note.","Interest rate 3.96% per annum, compound semi-annually; principal and interest due October 25, 2025.","Funds to be used for working capital and other expenses of OSR Holdings.","Default provisions include failure to pay within 5 business days of maturity and bankruptcy events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195895,"accession_number":"0001193125-24-241077","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bellevue Life Sciences SPAC issues $800K convertible promissory note to Duksung Co., Ltd.","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $800K, 5% simple interest; 7% if prepaid after March 31, 2025.","Automatically converts into common stock at $8.10/share upon Qualified PIPE closing (min $1.5M).","Qualified PIPE must occur before or simultaneously with business combination with OSR Holdings.","Maturity October 15, 2025; no prepayment before March 31, 2025 unless PIPE fails.","Note includes trust account waiver and escrow of 400K shares by BCM Europe AG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195894,"accession_number":"0001193125-24-237600","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Bellevue Life Sciences issues $40K note to director; deposits $50K to extend business combination","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $40,000 unsecured, interest-free promissory note to board member Jun Chul Whang, due Nov 9, 2024 or earlier upon business combination or additional working capital.","Principal will be forgiven if no business combination consummated by extended deadline, except for funds held outside trust account.","Deposited $50,000 into trust account on Oct 11, 2024 to further extend the deadline for completing a business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195893,"accession_number":"0001193125-24-235955","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Bellevue Life Sciences enters $20M PIPE with Toonon Partners for Series A Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreed to issue 222,222 Series A Preferred shares at $90/share to Toonon Partners for $20M total.","Proceeds to fund working capital after closing of business combination with OSR Holdings.","Series A Preferred carries 5% annual dividend, convertible into common at $9.00/share.","Company has redemption option after 1 year at 7% accrued; holders after 3 years.","PIPE closing conditioned on business combination completion and filing of Certificate of Designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195892,"accession_number":"0001193125-24-235949","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq panel grants Bellevue Life Sciences continued listing; must meet public holders rule by Feb 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice Feb 2024 for failing minimum 300 public holders; plan approved with extension to Aug 13, 2024.","Did not regain compliance by Aug 13; requested hearing which stayed suspension.","Hearing held Oct 1, 2024; Panel granted continued listing on Oct 4, 2024.","Must demonstrate compliance with Listing Rule 5505 by Feb 17, 2025, with prompt notification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212175,"accession_number":"0001193125-24-224807","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bellevue Life Sciences extends maturity on two director promissory notes to March 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended $75,000 promissory note from director Jun Chul Whang to March 31, 2025 or business combination.","Extended $60,000 promissory note from Josh Pan, sponsor affiliate, to same maturity trigger.","Amendments only change maturity; principal, interest, and other terms unchanged.","Moves maturity from earlier dates (Feb/Mar 2024) to give more time for SPAC deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212174,"accession_number":"0001193125-24-219608","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bellevue Life Sciences deposits $50k in trust to extend business combination deadline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$50,000 deposited into trust account on September 10, 2024.","Deposit made to extend deadline for consummating a business combination.","Tickers: BLACU, BLAC, BLACW, BLACR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212173,"accession_number":"0001193125-24-205378","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bellevue Life Sciences receives second Nasdaq delisting notice for insufficient public holders","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified company on Aug 20, 2024 that it failed to regain compliance with minimum 300 public holders requirement by Aug 13, 2024 deadline.","Company previously received initial notice on Feb 15, 2024 and submitted a compliance plan; extension granted until Aug 13, 2024.","Company intends to timely request a hearing before Nasdaq Hearings Panel, which will automatically stay suspension or delisting.","Securities affected: units (BLACU), common stock (BLAC), warrants (BLACW), rights (BLACR)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212172,"accession_number":"0001193125-24-202145","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bellevue Life Sciences deposits $50K to extend business combination deadline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deposited $50,000 into trust account on August 13, 2024 to extend deadline to complete initial business combination.","Extension provides additional time beyond original October 2024 termination date.","Company is a SPAC targeting life sciences acquisitions.","Common stock (BLAC), units (BLACU), warrants (BLACW), and rights (BLACR) trade on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212171,"accession_number":"0001193125-24-179674","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Bellevue Life Sciences SPAC extends deadline with $50K trust deposit; gets $300K sponsor loan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued $300,000 unsecured, non-interest bearing promissory note to sponsor Bellevue Global Life Sciences Investors LLC.","Note payable by Dec 31, 2024 or upon business combination; forgiven if no deal consummated, except trust funds.","Deposited $50,000 into trust account on July 12, 2024 to extend deadline for initial business combination.","SPAC has until extension deadline to complete a deal or risk liquidation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231077,"accession_number":"0001193125-24-169795","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bellevue Life Sciences Acquisition Appoints Sang Hyun Kim as Director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Sang Hyun Kim as director effective June 23, 2024; fills Audit, Compensation, and M&A Committee vacancies.","Mr. Kim is Special Advisor of Marketing, Private Equity Funds at Korea Daesung Asset Management Co., Ltd.","Has ~11 years at Samsung Group including Global M&A Strategy at Samsung Asset Management.","Board determined Mr. Kim meets Nasdaq independence standards; no compensation for director role.","Mr. Kim entered into standard Letter Agreement and Indemnity Agreement with BLAC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231076,"accession_number":"0001193125-24-160727","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["3.01","5.02","8.01"],"status":"ready","headline":"Two directors resign; Bellevue Life Sciences not compliant with Nasdaq listing rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Inchul Chung and Radclyffe Roberts resigned from Board and committees effective June 7, 2024, no dispute.","Company notified Nasdaq on June 13 of non-compliance with majority independent board, compensation and audit committee rules.","Company intends to regain compliance within applicable cure periods under Nasdaq rules.","Additionally, $50,000 contribution deposited into trust account on June 13."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231075,"accession_number":"0001193125-24-150364","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"BLAC amends business combo with OSR Holdings; cuts consideration, removes LBV target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended BCA reduces Aggregate Consideration to 24,461,214 shares ($244.6M) from 25,033,961 shares ($250.3M).","Removal of planned acquisition of Landmark BioVentures AG after LBV terminated LOI in March 2024.","Director Steven Reed resigned May 24; Phil Geon Lee appointed May 27 to audit, compensation, and M&A committees.","Jin Whan Park named Audit Committee chairman; Radclyffe Roberts named M&A Committee chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231074,"accession_number":"0001193125-24-138268","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["1.01","2.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Bellevue Life Sciences SPAC extends business combination deadline to Nov 14, 2024; 1.58M shares redeemed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved charter amendment to extend deadline from May 14 to Nov 14, 2024.","1,581,733 shares (approx. 28% of outstanding) tendered for redemption.","Sponsor BGLSI to deposit $50,000 monthly into trust for each of six months through Oct 15, 2024.","Company issued $140,000 unsecured promissory note to sponsor, non-interest bearing, due Dec 31, 2024 or upon business combination.","Promissory note forgiven if no business combination, except trust account funds outside trust."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231073,"accession_number":"0001193125-24-136788","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BLAC urges stockholders to vote for extension to Nov 14, 2024; meeting reconvenes May 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting reconvened May 14, 2024 to vote on extending business combination deadline to Nov 14, 2024.","Extension is needed to complete previously announced merger with OSR Holdings Co., Ltd. (South Korean healthcare holding company).","At least 65% of outstanding shares must vote in favor; failure to pass triggers SPAC liquidation.","Stockholders who tendered shares for redemption may reverse the tender prior to the vote on May 14.","Voting deadline is 11:59 PM ET on May 13, 2024; proxy solicitation by Advantage Proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231072,"accession_number":"0001193125-24-136088","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bellevue Life Sciences adjourns special meeting without vote; reconvenes May 14","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting convened May 10, 2024, was adjourned with no business conducted.","Meeting reconvenes May 14, 2024 at 9:00 a.m. PT at 925 Fourth Avenue, Suite 2900, Seattle.","Stockholders who tendered shares for redemption may withdraw tender before the vote.","Record date for voting remains April 18, 2024; proxies continue to be solicited.","Company seeks stockholder approval for proposals detailed in proxy statement filed April 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231071,"accession_number":"0001193125-24-104896","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["1.01","2.03","3.01","9.01"],"status":"ready","headline":"Bellevue Life Sciences gets Nasdaq extension to Aug 13, 2024 for 300 public holders; issues $50K note to sponsor","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq extension to demonstrate minimum 300 public holders by August 13, 2024; previously failed compliance.","Issued $50,000 unsecured promissory note to sponsor Bellevue Global Life Sciences Investors LLC, non-interest bearing.","Note due December 31, 2024 or upon initial business combination; principal forgiven if no deal consummated.","Failure to meet Nasdaq public-holder requirement by deadline could result in delisting of securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231070,"accession_number":"0000898432-24-000311","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Bellevue Life Sciences SPAC gets $1.2M sponsor note, extends deadline to May 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued $1.2M promissory note to sponsor, unsecured, no interest, due by Dec 31, 2024 or upon business combination.","Sponsor deposited $60,000 into trust to extend business combination deadline from April 15 to May 14, 2024.","Principal forgiven if no business combination occurs by charter deadline; sponsor waives trust account claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249474,"accession_number":"0000898432-24-000224","cik":1840425,"company_name":"OSR Holdings, Inc.","ticker":"OSRH","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Bellevue Life Sciences Acquisition Corp. issues $60K promissory note to Josh Pan for business combination extension","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On March 8, 2024, Bellevue Life Sciences issued a $60,000 unsecured promissory note to Josh Pan, member of sponsor Bellevue Capital Management, LLC.","Note is non-interest bearing, due August 8, 2024 or upon consummation of an initial business combination, with principal forgiven if no deal occurs.","On March 12, 2024, $60,000 deposited into trust account to extend business combination deadline from March 14, 2024 to April 15, 2024.","Event of default includes payment failure within five business days of maturity or bankruptcy proceedings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16990818.044444446,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-03-13T23:59:59+00:00|249474"}